What question did this study set out to answer?

To evaluate the long-term efficacy and safety of dostarlimab plus chemotherapy in patients with dMMR/MSI-H endometrial cancer.

July 4, 2026Open Access

71RO Sustained remission and long-term survival outcomes with dostarlimab plus chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

Key Points

To evaluate the long-term efficacy and safety of dostarlimab plus chemotherapy in patients with dMMR/MSI-H endometrial cancer.
Randomized clinical trial design (ENGOT-EN6-NSGO/GOG-3031/RUBY) with NCT03981796 registry ID.
Involved patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Follow-up duration of 4 years to assess long-term outcomes.
Dostarlimab plus chemotherapy significantly improved progression-free survival (PFS) compared to previous treatments.
Clinically meaningful overall survival (OS) benefits were observed in the treatment group.
Patients showed characteristics of long-term disease control beyond the initial treatment phase.

Abstract

Dostarlimab + carboplatin-paclitaxel (DOST+CP) demonstrated statistically significant PFS and clinically meaningful OS benefits in patients (pts) with dMMR/MSI-H primary advanced or recurrent endometrial cancer (pA/R EC) in Part 1 of the phase III RUBY trial (NCT03981796). Here, we report updated efficacy with 4 y of follow-up in pts with dMMR/MSI-H pA/R EC and further summarized characteristics of pts with long-term disease control.

Read Full Paperexternally

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper